Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
IPO Year: 1996
Exchange: NASDAQ
Website: geron.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $1.00 | Sell | Goldman |
| 5/8/2025 | $1.50 | Sector Outperform → Sector Perform | Scotiabank |
| 2/27/2025 | $3.50 → $2.00 | Buy → Neutral | B. Riley Securities |
| 2/26/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | $8.00 | Buy | H.C. Wainwright |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $7.00 | Outperform | Leerink Partners |
| 4/30/2024 | $4.50 | Outperform → Neutral | Robert W. Baird |
| 4/29/2024 | $10.00 | Buy | TD Cowen |
| 3/15/2024 | $4.00 → $5.00 | Buy | Needham |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00
Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50
B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously
H.C. Wainwright downgraded Geron from Buy to Neutral
H.C. Wainwright initiated coverage of Geron with a rating of Buy and set a new price target of $8.00
Scotiabank initiated coverage of Geron with a rating of Sector Outperform
Leerink Partners initiated coverage of Geron with a rating of Outperform and set a new price target of $7.00
Robert W. Baird downgraded Geron from Outperform to Neutral and set a new price target of $4.50
TD Cowen initiated coverage of Geron with a rating of Buy and set a new price target of $10.00
Needham reiterated coverage of Geron with a rating of Buy and set a new price target of $5.00 from $4.00 previously
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
8-K - GERON CORP (0000886744) (Filer)
SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
10-Q - GERON CORP (0000886744) (Filer)
DEFA14A - GERON CORP (0000886744) (Filer)
DEF 14A - GERON CORP (0000886744) (Filer)
SCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
8-K - GERON CORP (0000886744) (Filer)
S-3ASR - GERON CORP (0000886744) (Filer)
10-K - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
Fastest customizable press release news feed in the world
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL. A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron's website at www.geron.com. About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our firs
Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Associa
Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare ConferencePresentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV 2026 Stifel Virtual Targeted Oncology ForumVirtual presentation on Wednesday, May 20 at 12:00 p.m. ET A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About Ge
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About GeronGero
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron's new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron. The stock option was granted on April 13, 2026. The stock option has an exercise price of $1.73 per share, which is equal to the closing price of Geron's common stock on the grant date, has a ten-year term and vests over four years, with 12.5% of the shares un
FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. "Tim has deep expertise in the biopharmaceutical industry and a proven track record of leading the legal function at commercial-stage organizations," said Harout Semerjian, President and Chief Executive Officer of Geron. "The addition of Tim, coupled with our recent Board appointments, further strengthens our leadership team. His strategic counsel will be invaluable as we
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
3 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
3 - GERON CORP (0000886744) (Issuer)
Live Leadership Updates
FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. "Tim has deep expertise in the biopharmaceutical industry and a proven track record of leading the legal function at commercial-stage organizations," said Harout Semerjian, President and Chief Executive Officer of Geron. "The addition of Tim, coupled with our recent Board appointments, further strengthens our leadership team. His strategic counsel will be invaluable as we
FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. "We are pleased to welcome Constantine and Pat to the Board, as they bring deep operational expertise cultivated over decades of biopharmaceutical industry leadership, particularly with commercial-stage organizations," said Elizabeth O'Farrell, Chair of the Board. "Their invaluable insights will be instrumental as we execute on our strategic priorities and drive commercial growth for RYTE
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commer
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria
Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron's next phase of growth Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow. Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron's Board of Directors, where she will contribute her insight and strategic counsel. "Our Board conducted an extens
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
This live feed shows all institutional transactions in real time.
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13D/A - GERON CORP (0000886744) (Subject)
SC 13G - GERON CORP (0000886744) (Subject)
Live finance-specific insights
Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare ConferencePresentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV 2026 Stifel Virtual Targeted Oncology ForumVirtual presentation on Wednesday, May 20 at 12:00 p.m. ET A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About Ge
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About GeronGero
Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.c
Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team with appointment of Chief Commercial Officer and additional key executives Announced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting Company to host conference call and webcast today, November 5, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 an
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website. About Geron Geron is a com
Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in RYTELO® net product revenue in Q2 2025 Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and expected to be fully enrolled by year-end Company to host conference call and webcast today, August 6, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of H
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and business highlights before the market opens on Wednesday, August 6, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website for 30 days. About Geron Geron i
Reported $39.4 million in RYTELO® (imetelstat) net product revenue in Q1 2025; revenue impacted by inventory dynamics, with Q1 demand relatively flat Granted marketing authorization of RYTELO by the European Commission (EC); planning for commercial launch in select EU countries 2026 Reached approximately 85% enrollment in the Phase 3 IMpactMF clinical trial for treatment of relapsed/refractory myelofibrosis; interim analysis remains expected in 2H 2026 Company to host conference call and webcast today, May 7 at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial